List of Excipients in Branded Drug CETIRIZINE HYDROCHLORIDE TABLETS,10 MG

« Back to Dashboard

Generic Drugs Containing CETIRIZINE HYDROCHLORIDE TABLETS,10 MG

Company	Ingredient	NDC	Excipient
TIME CAP LABORATORIES INC	cetirizine hydrochloride	49483-692	HYPROMELLOSES
TIME CAP LABORATORIES INC	cetirizine hydrochloride	49483-692	LACTOSE MONOHYDRATE
TIME CAP LABORATORIES INC	cetirizine hydrochloride	49483-692	MAGNESIUM STEARATE
TIME CAP LABORATORIES INC	cetirizine hydrochloride	49483-692	POLYETHYLENE GLYCOL

What are the Most Frequently-Used Excipients in CETIRIZINE HYDROCHLORIDE TABLETS,10 MG?

# Of NDCs	Excipient
2	HYPROMELLOSES
2	LACTOSE MONOHYDRATE
2	MAGNESIUM STEARATE
2	POLYETHYLENE GLYCOL

Cetirizine Hydrochloride 10 mg Tablets: Excipient Strategy, Formulation Design and Commercial Opportunities

Last updated: August 11, 2026

Cetirizine hydrochloride 10 mg tablets are mature, low-cost immediate-release antihistamine products with limited active-ingredient patent protection and strong generic competition. Commercial differentiation depends on manufacturability, tablet performance, packaging, pediatric or senior-friendly delivery, and channel economics rather than new chemical-entity exclusivity.

The most competitive base formulation is a small, robust immediate-release tablet using microcrystalline cellulose, lactose or mannitol, a superdisintegrant, colloidal silicon dioxide, and magnesium stearate. Higher-margin opportunities include orally disintegrating tablets, chewable tablets, alcohol-free pediatric liquids, unit-dose allergy packs, and differentiated packaging.

What is cetirizine hydrochloride 10 mg used for?

Cetirizine hydrochloride is a second-generation H1 antihistamine indicated for allergic rhinitis and chronic urticaria. The standard adult and adolescent dose is 10 mg once daily, while lower doses are commonly used in younger children and patients with renal impairment under product labeling or clinical direction [1].

Attribute	Product profile
Active ingredient	Cetirizine hydrochloride
Strength	10 mg per tablet
Dosage form	Immediate-release tablet
Therapeutic class	Second-generation H1 antihistamine
Main uses	Seasonal allergic rhinitis, perennial allergic rhinitis, chronic urticaria
Typical adult dosing	10 mg once daily
Prescription and OTC status	Both markets exist, depending on jurisdiction and product
Reference product	Zyrtec and other cetirizine products
Primary commercial competitors	Loratadine, desloratadine, fexofenadine, levocetirizine
Biosimilar relevance	None; cetirizine is a small molecule
Main differentiation levers	Price, onset messaging, sedation positioning, dosage form, packaging, tolerability, supply reliability

Cetirizine is usually sold as a conventional film-coated or uncoated tablet. The 10 mg dose creates a favorable formulation profile because the active load is small relative to the total tablet mass. That allows manufacturers to optimize flow, compression, disintegration, and appearance with conventional excipients.

What excipients are used in cetirizine hydrochloride 10 mg tablets?

Published product labels show that excipients differ by manufacturer and market. Common excipient classes include diluents, binders, disintegrants, glidants, lubricants, film-coating polymers, plasticizers, and colorants.

Typical excipient architecture

Functional role	Common excipients	Formulation purpose
Diluent	Microcrystalline cellulose, lactose monohydrate, mannitol, dibasic calcium phosphate	Provides bulk and improves compression
Binder	Povidone, pregelatinized starch, hydroxypropyl cellulose	Improves granule or tablet strength
Disintegrant	Crospovidone, sodium starch glycolate, croscarmellose sodium	Promotes tablet breakup after ingestion
Glidant	Colloidal silicon dioxide	Improves powder flow and die filling
Lubricant	Magnesium stearate, sodium stearyl fumarate	Reduces ejection force and tooling adhesion
Film former	Hypromellose, polyvinyl alcohol	Provides appearance, swallowability, and moisture protection
Plasticizer	Polyethylene glycol, propylene glycol	Improves coating flexibility
Opacifier or colorant	Titanium dioxide, iron oxides, permitted lakes	Controls appearance and product identification
Sweetener or flavor	Sucralose, aspartame, mannitol, flavor systems	Supports chewable or orally disintegrating formats

The exact choice should follow the target product profile. A low-cost generic tablet should minimize excipient count and avoid expensive specialty systems unless they solve a measurable manufacturing or commercial problem.

How should a manufacturer design a conventional cetirizine tablet?

A conventional 10 mg tablet should prioritize rapid disintegration, consistent assay, low friability, efficient compression, and stable packaging.

Direct compression strategy

Direct compression is generally the most attractive process for a low-dose, immediate-release tablet when the API and excipient blend have acceptable flow and content-uniformity characteristics.

A representative platform may use:

• Microcrystalline cellulose as the primary compression aid
• Lactose monohydrate or mannitol as a secondary diluent
• Crospovidone or croscarmellose sodium as the disintegrant
• Colloidal silicon dioxide as the glidant
• Magnesium stearate at a controlled concentration and blending time

Direct compression reduces processing steps, solvent use, drying requirements, and manufacturing cost. The main development risks are segregation, API distribution, lubricant sensitivity, and weight variation.

Dry granulation strategy

Roller compaction or slugging may be appropriate where the API blend has poor flow, low bulk density, or unacceptable segregation. Dry granulation can improve:

• Blend uniformity
• Hopper flow
• Tablet weight control
• Compression behavior
• Scale-up consistency

The tradeoff is a more complex process with potential effects on granule porosity, tablet tensile strength, and disintegration. Excessive compaction can produce hard granules that delay drug release.

Wet granulation strategy

Wet granulation is generally less attractive for a simple cetirizine product unless direct compression and dry granulation fail. It can improve content uniformity and compressibility, but introduces water or solvent exposure, drying requirements, and additional process controls.

The strategy may be justified when:

• The API has poor flow
• The target tablet is unusually small
• The formulation requires a high level of fine powder
• The product needs improved mechanical strength
• The manufacturing site already has a validated wet-granulation platform

What excipient choices improve cetirizine tablet performance?

Microcrystalline cellulose versus lactose

Microcrystalline cellulose provides strong compactibility and is useful for direct compression. It can support small, robust tablets with low friability. Lactose can improve mouthfeel and cost efficiency but may have different moisture and compaction behavior depending on grade.

A combination of microcrystalline cellulose and lactose is often more flexible than relying on either excipient alone. Spray-dried lactose is more suitable for direct compression than some conventional lactose grades.

Crospovidone versus croscarmellose sodium

Crospovidone usually provides rapid wicking and disintegration with limited gelling. Croscarmellose sodium provides strong swelling and can perform well at low concentrations. The choice should be based on:

• Disintegration time
• Dissolution profile
• Tablet hardness
• Sensitivity to compression force
• Moisture exposure
• Supplier cost and continuity

Sodium starch glycolate can provide effective swelling but may be more sensitive to overuse or excessive compression.

Magnesium stearate versus sodium stearyl fumarate

Magnesium stearate is inexpensive and widely available but can slow wetting or dissolution if over-lubrication occurs. Blending time and shear should be controlled. Sodium stearyl fumarate can be useful where improved dissolution or reduced hydrophobicity is needed, although its cost may be higher.

Lactose-free and sugar-free platforms

Mannitol is attractive for chewable and orally disintegrating products because it provides a cooling sensation and improved palatability. It is also suitable for sugar-free positioning. The cost is usually higher than basic lactose-based systems.

A lactose-free platform can support consumers with lactose avoidance preferences, although the commercial value depends on local labeling rules and consumer demand.

What formulations are protected by cetirizine patents?

Cetirizine hydrochloride 10 mg tablets do not generally present the patent barriers associated with recently launched small molecules. The original compound and early product protections are expired or commercially immaterial in major markets. Current competition is primarily based on abbreviated applications, OTC monographs, trademarks, manufacturing efficiency, and formulation execution.

Potentially relevant intellectual-property areas include:

• Orally disintegrating dosage forms
• Taste-masked particles
• Fixed-dose combinations
• Modified-release systems
• Pediatric delivery systems
• Novel packaging or dispensing systems
• Manufacturing processes
• Specific excipient ratios or granulation methods

The practical risk is usually not a basic cetirizine tablet patent. It is the possibility that a proposed differentiated formulation reads on a narrow formulation or delivery patent in a particular jurisdiction.

What is the Orange Book status of cetirizine hydrochloride tablets?

Cetirizine products have a mature FDA regulatory history. FDA-approved prescription products and listed reference products may appear in Drugs@FDA and the Orange Book, while OTC products are governed by the applicable OTC regulatory framework and product-specific labeling requirements [2, 3].

For a conventional generic 10 mg tablet, the regulatory route depends on the reference product and market status:

Product route	Main regulatory feature
Prescription generic	ANDA demonstrating pharmaceutical equivalence and bioequivalence
OTC monograph product	Compliance with applicable monograph conditions and labeling
NDA OTC product	Product-specific NDA requirements
Pediatric or novel delivery form	May require additional formulation, labeling, and performance support
Combination product	Separate regulatory and labeling analysis

A manufacturer should verify current Orange Book listings, reference standards, patents, exclusivity, and application status before filing. A historical reference product entry does not by itself establish current commercial exclusivity.

When does cetirizine lose exclusivity?

Cetirizine has already passed the principal exclusivity period associated with its original prescription launch. Generic and private-label competition is established in the United States and many international markets.

The commercial exclusivity timeline is best understood as follows:

Milestone	Commercial implication
Original prescription launch	Initial branded market formation
Generic entry	Price competition and broad multi-source supply
OTC switch	Expansion into mass retail and consumer self-selection
Mature OTC market	Private-label and retailer competition dominate
Current stage	Differentiation depends on cost, delivery format, and channel execution

Cetirizine does not have biosimilar risk because it is a chemically synthesized small molecule. The relevant competitive threat is generic substitution and brand-to-private-label switching.

Which companies are challenging cetirizine hydrochloride products?

Cetirizine is challenged by a broad field of generic manufacturers, OTC marketers, contract manufacturers, and retailer-owned brands. The competitive set varies by country and changes frequently as products enter or leave the market.

The relevant competitor categories are:

1. Large generic manufacturers with ANDA or equivalent approvals.
2. Consumer-health companies selling branded cetirizine.
3. Retail chains selling private-label cetirizine.
4. Contract development and manufacturing organizations supplying store brands.
5. Regional manufacturers competing on price and government tenders.

A complete current list of active applicants and litigation parties requires a live review of FDA application databases, Orange Book entries, court dockets, and national registers. The basic 10 mg tablet market is generally characterized by high supplier density and low switching costs.

What patent litigation affects cetirizine?

Cetirizine is not commonly associated with active, high-value patent litigation over the basic 10 mg immediate-release tablet. Litigation risk is more likely to arise from:

• Trademarks and trade dress
• OTC advertising claims
• Labeling and consumer-protection issues
• Narrow formulation patents
• Combination products
• Manufacturing or supply agreements
• Product liability claims

A Paragraph IV challenge is theoretically available against an unexpired listed patent for a qualifying reference product, but the commercial importance of such a challenge depends on whether any enforceable patent remains listed for the exact proposed product.

How strong is the cetirizine patent estate?

The patent estate for the basic cetirizine hydrochloride tablet is weak from a lifecycle-management perspective because the active ingredient is mature and the standard dosage form is widely available.

Patent category	Relative strength for basic 10 mg tablets
Original compound patent	Expired or commercially inactive
Standard immediate-release tablet	Low
Basic excipient combination	Low unless narrowly claimed and technically differentiated
Orally disintegrating formulation	Moderate, depending on claims and jurisdiction
Taste-masking technology	Moderate where supported by specific claims
Fixed-dose combination	Moderate to strong if claims remain enforceable
Manufacturing process	Variable; often narrow and design-around possible
Packaging and dispensing	Usually narrow and commercially limited

A new formulation patent is more defensible when it has a defined technical effect, such as improved dissolution under a specific condition, enhanced stability, reduced degradation, improved taste, or a reproducible manufacturing advantage.

What are the best excipient-led commercial opportunities?

Orally disintegrating tablets

An orally disintegrating tablet can target consumers who have difficulty swallowing conventional tablets or who want administration without water. The formulation must balance:

• Fast disintegration
• Mechanical strength
• Taste masking
• Low friability
• Moisture protection
• Packaging cost

Mannitol, crospovidone, flavor, sweetener, and a taste-masking approach are common design elements. Aluminum-aluminum blister packaging or high-barrier unit-dose packaging may be required because ODTs are often more moisture-sensitive than conventional tablets.

Chewable tablets

Chewable cetirizine tablets can support pediatric and convenience positioning. The main technical barrier is taste. Cetirizine can require effective bitterness control, particularly at higher local concentrations during chewing.

Useful approaches include:

• Mannitol-based matrices
• Flavor and sweetener systems
• Polymer coating of API particles
• Ion-exchange resin complexes
• Granulated taste-masked API
• Controlled particle-size distribution

Taste masking must be assessed in human or validated sensory studies, not inferred from dissolution alone.

Pediatric products

Pediatric opportunities include lower-strength tablets, chewables, oral solutions, and unit-dose sachets. The 10 mg tablet can support scored or divisible formats, but dose accuracy after splitting must be demonstrated.

Excipients require additional scrutiny for:

• Sugar content
• Polyols and gastrointestinal tolerance
• Sodium load
• Preservatives
• Colorants
• Aspartame or other sweeteners
• Ethanol
• Propylene glycol
• Benzyl alcohol and other age-sensitive excipients

Senior-friendly and adherence-focused products

Large consumer markets contain users who have dysphagia, poor dexterity, or difficulty opening bottles. Commercial options include:

• Easy-open but child-resistant packaging combinations
• Calendarized blister packs
• Large-print labeling
• Scored tablets
• ODT delivery
• Unit-dose pouches
• Color-coded seasonal allergy packs

These are often more commercially feasible than attempting to create a new pharmacological benefit.

Premium packaging and seasonal bundles

Cetirizine demand is seasonal in many markets. Packaging can support:

• 30-, 90-, and 365-count configurations
• Pollen-season multipacks
• Travel-size blister packs
• Allergy and eye-drop bundles
• Retailer-exclusive designs
• E-commerce subscription packs

The opportunity is operational rather than patent-driven. It depends on shelf placement, retailer margins, inventory planning, and supply reliability.

How does cetirizine compare with loratadine and fexofenadine?

Cetirizine competes in the once-daily, non-sedating or low-sedation antihistamine segment. Product positioning should account for consumer perceptions and label claims rather than assume all products have identical tolerability.

Factor	Cetirizine	Loratadine	Fexofenadine
Standard adult dose	Commonly 10 mg once daily	Commonly 10 mg once daily	Commonly 120 or 180 mg once daily, depending on indication
Common formats	Tablets, chewables, liquids, ODTs	Tablets, chewables, liquids, ODTs	Tablets, liquids, selected specialty formats
Main consumer positioning	Allergy and hives relief	Long-lasting allergy relief	Non-drowsy positioning
Tablet excipient opportunity	Taste masking and rapid disintegration	Similar	Larger API load and different compression profile
Generic competition	High	High	High
Primary differentiation	Price, perceived onset, dosage form	Brand recognition and broad OTC availability	Non-drowsy positioning and brand equity

Cetirizine may have a stronger opportunity for premium ODT and chewable formats than a basic tablet because its 10 mg dose is compact and easy to package. Fexofenadine products may have a different tablet-engineering profile because of the higher active load.

What manufacturing and IP barriers affect commercialization?

The main manufacturing barriers are manageable but can affect gross margin:

• Low-dose content uniformity
• API segregation
• Lubricant overmixing
• Moisture sensitivity in ODT formats
• Taste masking without delayed release
• Tablet capping and lamination
• Packaging barrier requirements
• Seasonal demand volatility
• Multiple-market excipient restrictions

A conventional tablet can often be developed with widely available excipients and standard equipment. A taste-masked ODT requires more specialized process knowledge, sensory testing, and packaging. That creates a stronger barrier to entry but also increases development cost.

Excipient suppliers can create indirect supply risk where a formulation depends on a specific grade of co-processed excipient, taste-masking polymer, or directly compressible mannitol. Dual sourcing should be evaluated early, because replacing an excipient grade can alter dissolution, hardness, friability, and blend uniformity.

What generic launch scenarios exist for cetirizine 10 mg tablets?

Low-cost standard tablet

This is the lowest-risk route and the most crowded segment. Success depends on:

• Low conversion cost
• High line utilization
• Reliable API sourcing
• Low packaging cost
• Retail or tender access
• Strong quality metrics

Premium generic ODT

This route supports higher unit pricing and improved consumer convenience. It requires greater investment in taste masking, moisture control, stability, and packaging.

Pediatric chewable

A chewable product can access family and pediatric channels. The principal development risk is taste acceptance and excipient suitability.

Private-label platform

A single validated formulation can support several retailer labels, pack sizes, and jurisdictions. This approach improves manufacturing scale but requires flexible artwork, packaging, and regulatory control.

Hospital and institutional supply

Institutional buyers often prioritize price, delivery reliability, and quality documentation. A simple uncoated or film-coated tablet may be preferable to a premium dosage form.

What is the revenue exposure for cetirizine products?

Revenue exposure is driven by volume rather than exclusivity. The standard tablet is vulnerable to rapid price erosion because multiple manufacturers can supply an interchangeable product. The strongest revenue opportunities are usually:

• Retailer private labels
• Large-count value packs
• Seasonal inventory programs
• Pediatric dosage forms
• ODT and chewable products
• Contract manufacturing
• Geographic expansion into markets with lower generic penetration

A basic 10 mg tablet is unlikely to sustain a meaningful premium without a differentiated channel, package, or consumer benefit. A premium formulation can improve gross margin, but its value must offset sensory testing, specialized packaging, and regulatory costs.

Key Takeaways

• Cetirizine hydrochloride 10 mg tablets are mature generic and OTC products with limited basic-tablet patent protection.
• Direct compression is the leading cost-efficient development strategy when powder flow and content uniformity are acceptable.
• Microcrystalline cellulose, lactose or mannitol, crospovidone or croscarmellose sodium, colloidal silicon dioxide, and magnesium stearate provide a practical excipient platform.
• ODT and chewable products offer stronger commercial differentiation than another conventional tablet.
• Taste masking, moisture protection, and pediatric excipient review are the main technical issues for differentiated products.
• Biosimilar risk is irrelevant; generic substitution is the primary competitive threat.
• A standard tablet is a scale and cost business. A differentiated dosage form is a formulation, packaging, and channel business.
• Patent value is limited for the basic product but may remain relevant for narrow taste-masking, ODT, combination, manufacturing, or delivery claims.
• Private-label manufacturing and seasonal allergy packaging offer practical commercial opportunities.
• Current FDA Orange Book, Drugs@FDA, OTC monograph, patent, and litigation records should govern any filing or launch decision.

FAQs About Cetirizine Hydrochloride 10 mg Tablet Formulation

Which disintegrant is best for cetirizine 10 mg tablets?

Crospovidone and croscarmellose sodium are leading candidates. The choice should be based on dissolution, disintegration, tablet strength, moisture exposure, and lubricant sensitivity.

Can cetirizine hydrochloride 10 mg tablets be made by direct compression?

Yes, direct compression is a practical starting process when the API blend has suitable flow and content-uniformity performance. Segregation and lubrication studies are essential because the active dose is relatively low.

What is the best excipient for a cetirizine orally disintegrating tablet?

Mannitol is commonly attractive for mouthfeel and cooling sensation, while crospovidone can provide rapid disintegration. Neither addresses bitterness alone, so taste masking may be required.

Does cetirizine have biosimilar competition?

No. Cetirizine is a chemically synthesized small molecule. Its relevant competitors are generic, branded-generic, OTC, and private-label products.

Is a new cetirizine formulation likely to receive strong patent protection?

A basic reformulation is unlikely to create strong protection unless the product has specific, demonstrable technical advantages and claims that distinguish it from prior art. Taste-masking systems, ODT platforms, combinations, and manufacturing processes may offer more defensible claim scope.

References

1. U.S. Food and Drug Administration. (2018). Zyrtec (cetirizine hydrochloride) prescribing information. FDA Drugs@FDA.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugsatfda

3. U.S. Food and Drug Administration. (n.d.). Over-the-counter drug monograph system. https://www.fda.gov/drugs/over-counter-otc-nonprescription-medicines

4. U.S. Food and Drug Administration. (2017). Food-effect bioavailability and fed bioequivalence studies. Guidance for Industry.

5. U.S. Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. USP Convention.

6. European Medicines Agency. (n.d.). Cetirizine-containing medicinal products: Product information and regulatory resources. https://www.ema.europa.eu